Filtered By:
Vaccination: Pneomococcal Vaccine

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 303 results found since Jan 2013.

Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial
CONCLUSIONS: Immune responses after coadministration of PCV20 and QIV were noninferior to separate administration of either vaccine. The PCV20 safety profile was similar when given together with or after QIV. These findings support PCV20 and QIV coadministration.TRIAL REGISTRATION: ClinicalTrials.gov, NCT04526574.PMID:36828719 | DOI:10.1016/j.vaccine.2022.11.046
Source: Vaccine - February 24, 2023 Category: Allergy & Immunology Authors: Kevin Cannon Jose F Cardona Kari Yacisin Allison Thompson Todd J Belanger Dung-Yang Lee Yahong Peng Lisa Moyer John Ginis William C Gruber Daniel A Scott Wendy Watson Source Type: research

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

A case of giant primary splenic hydatid cyst: Case report
We present a case of 29-year male patient from rural areas presented with the complain of left hypochondriac pain and tenderness along with the history of farming and cattle raising. There was no other significant history.CLINICAL FINDINGS AND INVESTIGATIONS: Physical examination showed mildly distended abdomen, mild tenderness over left hypochondrium. Routine laboratory investigations were sent. Ultrasound and CT scan of the abdomen showed giant splenic cyst measuring approx. 15 × 14 × 11 cm along with daughter cysts. Postoperatively, cyst was sent for histopathological examination.INTERVENTION AND OUTCOME: Preoperative...
Source: Annals of Medicine - December 30, 2022 Category: Internal Medicine Authors: Sampurna Singh Shreeja Kisee Suprabha Amatya Santosh Singh Shiwani Bista Rajan Shrestha Milan Kumar Chhantel Thapa Source Type: research

The safety of COVID-19 vaccines in patients with myasthenia gravis: A scoping review
ConclusionCOVID-19 vaccines may cause new-onset or worsening of MG in a small proportion of population. Large-scale, multicenter, prospective, and rigorous studies are required to verify their safety.
Source: Frontiers in Immunology - December 22, 2022 Category: Allergy & Immunology Source Type: research

China ’s Stunning U-Turn on Zero-COVID Takes Xi Jinping From Suffocating Control to Callous Inaction
Even for China, where the distance between official narrative and empirical evidence is often a chasm, the last few days have been jarring. On Tuesday, officials announced five deaths from COVID-19—up from two the previous day, which were the first recorded in the country since Dec. 3. On Wednesday, there were officially none. But a glance online tells a different story. Dozens of hearses line up at a Beijing crematorium; bodies wrapped in orange plastic pile in hospitals; patients on ventilators are crammed on a ward floor. [time-brightcove not-tgx=”true”] The decision by Chinese Communist Party (CCP) le...
Source: TIME: Health - December 21, 2022 Category: Consumer Health News Authors: Charlie Campbell / Singapore Tags: Uncategorized China Londontime overnight Source Type: news

Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality?
COVID-19 first emerged in Wuhan, China, in December 2019, resulting in a rapid spread in the outbreak of pneumonia. The pandemic has affected millions of individuals and claimed more than 6 million lives worldwide, leading to massive health, social, and economic issues (Cascella et  al., 2022). Patients with COVID-19 often experience fatigue, fever, cough, pneumonia, and acute respiratory distress syndrome at the advanced stages (Shirani et al., 2020). Except for respiratory symptoms, COVID-19 might be directly or indirectly linked to severe cardiovascular complications, suc h as palpitation, chest pain, and acute cardio...
Source: International Journal of Infectious Diseases - September 5, 2022 Category: Infectious Diseases Authors: Yiran E. Li, Shuyi Wang, Russel J. Reiter, Jun Ren Tags: Review Source Type: research

Clinical Cardiovascular Emergencies and the Cellular Basis of COVID-19 Vaccination: from a Dream to Reality?
Coronavirus disease 2019 (COVID-19) first emerged in Wuhan, China in December 2019, resulting in a rapidly spread in the outbreak of pneumonia. The pandemic has affected millions of individuals and claimed more than 6 million lives worldwide, leading to massive health, social and economic issues (Cascella et al., 2022). COVID-19 patients often suffer from fatigue, fever, cough, pneumonia and acute respiratory distress syndrome (ARDS) at the advanced stages (Shirani et al., 2020). Except for respiratory symptoms, COVID-19 might be directly or indirectly linked to severe cardiovascular complications, such as palpitation, che...
Source: International Journal of Infectious Diseases - September 5, 2022 Category: Infectious Diseases Authors: Yiran E. Li, Shuyi Wang, Russel J. Reiter, Jun Ren Tags: Review Source Type: research

A case of COVID ‐19‐associated fulminant myocarditis successfully treated with mechanical circulatory support
AbstractA 49-year-old man, who had not been vaccinated against COVID-19 visited the hospital for fever and cough, and a PCR test for COVID-19 was positive on the Day X. Initially, there was no decrease in oxygen saturation and the patient was under observation as a mild case without medication. Five days after the onset (Day X  + 5), chest pain appeared. Electrocardiogram showed widespread ST-segment elevation, and blood tests showed high levels of troponin I. However, given that there was no stenotic lesion on coronary computed tomography, myocarditis was suspected, and he was transferred to our hospital on the Day X ...
Source: Clinical Case Reports - September 3, 2022 Category: General Medicine Authors: Ryosuke Asakura, Tatsuki Kuroshima, Naohiro Kokita, Motoi Okada Tags: CASE REPORT Source Type: research